A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

연구 개요

This study aims to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of GSK3745417 administered alone (Part 1A) or co-administered (Part 2A) with dostarlimab in participants with refractory/relapsed solid tumors. Both parts will consist of a dose escalation phase.